CO7020851A2 - Proteínas y péptidos modificados - Google Patents

Proteínas y péptidos modificados

Info

Publication number
CO7020851A2
CO7020851A2 CO14029997A CO14029997A CO7020851A2 CO 7020851 A2 CO7020851 A2 CO 7020851A2 CO 14029997 A CO14029997 A CO 14029997A CO 14029997 A CO14029997 A CO 14029997A CO 7020851 A2 CO7020851 A2 CO 7020851A2
Authority
CO
Colombia
Prior art keywords
proteins
modified peptides
peptides
modified
Prior art date
Application number
CO14029997A
Other languages
English (en)
Spanish (es)
Inventor
Claire Ashman
Mary Birchler
Wildt Rudolf M T De
Claire Holland
Alan Peter Lewis
Peter Morley
Thomas Sandal
Michael Steward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1121226.3A external-priority patent/GB201121226D0/en
Priority claimed from GBGB1121236.2A external-priority patent/GB201121236D0/en
Priority claimed from GBGB1121233.9A external-priority patent/GB201121233D0/en
Priority claimed from PCT/EP2012/064632 external-priority patent/WO2013014208A2/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO7020851A2 publication Critical patent/CO7020851A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
CO14029997A 2011-08-17 2014-02-12 Proteínas y péptidos modificados CO7020851A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161524488P 2011-08-17 2011-08-17
GBGB1121226.3A GB201121226D0 (en) 2011-12-12 2011-12-12 Modified proteins and peptides
GBGB1121236.2A GB201121236D0 (en) 2011-12-12 2011-12-12 Proteins and peptides
GBGB1121233.9A GB201121233D0 (en) 2011-12-12 2011-12-12 Modified proteins and peptides
PCT/EP2012/064632 WO2013014208A2 (en) 2011-07-27 2012-07-25 Antigen binding constructs

Publications (1)

Publication Number Publication Date
CO7020851A2 true CO7020851A2 (es) 2014-08-11

Family

ID=47715521

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14029997A CO7020851A2 (es) 2011-08-17 2014-02-12 Proteínas y péptidos modificados

Country Status (25)

Country Link
US (3) US10808040B2 (https=)
EP (3) EP2744822B1 (https=)
JP (3) JP6297976B2 (https=)
KR (2) KR102143506B1 (https=)
CN (2) CN108178800B (https=)
AR (1) AR087521A1 (https=)
AU (3) AU2012296961B2 (https=)
BR (1) BR112014003679B1 (https=)
CA (1) CA2845029A1 (https=)
CO (1) CO7020851A2 (https=)
DO (1) DOP2014000029A (https=)
EA (1) EA027160B1 (https=)
ES (1) ES2813432T3 (https=)
HK (1) HK1214281A1 (https=)
IL (1) IL230918A0 (https=)
MA (1) MA35428B1 (https=)
MX (1) MX2014001883A (https=)
MY (1) MY167125A (https=)
PE (1) PE20141522A1 (https=)
PH (1) PH12014500380A1 (https=)
SG (2) SG2014010482A (https=)
TW (1) TW201321405A (https=)
UA (1) UA118833C2 (https=)
UY (1) UY34254A (https=)
WO (1) WO2013024059A2 (https=)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2494046B1 (en) 2009-10-30 2018-09-12 Novartis AG Universal fibronectin type iii bottom-side binding domain libraries
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
CN106046168A (zh) 2011-06-23 2016-10-26 埃博灵克斯股份有限公司 结合血清白蛋白的蛋白
DK2723769T4 (da) * 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
EP2944653A1 (en) * 2011-06-23 2015-11-18 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
DK2974737T3 (da) * 2011-06-23 2026-01-19 Ablynx Nv Fremgangsmåder til forudsigelse, påvisning og reduktion af en specifik proteininterferens i assays, der involverer variable immunglobulin-enkeltdomæner
SG2014010482A (en) * 2011-08-17 2014-04-28 Glaxo Group Ltd Modified proteins and peptides
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
JP2015531350A (ja) * 2012-09-13 2015-11-02 ノバルティス アーゲー 末端修飾を有する抗原結合分子
WO2014111550A1 (en) * 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
WO2015104322A1 (en) * 2014-01-09 2015-07-16 Glaxosmithkline Intellectual Property Development Limited Treatment of inflammatory diseases with non-competitive tnfr1 antagonists
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
PL3248986T3 (pl) * 2014-05-16 2022-05-16 Ablynx Nv Domeny zmienne immunoglobuliny
ES2900852T3 (es) 2014-05-16 2022-03-18 Ablynx Nv Métodos de detección y/o medición de anticuerpos anti-fármaco, en particular anticuerpos anti-fármaco que se presentan durante el tratamiento
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
EA201790719A1 (ru) * 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
EP3271391A1 (en) * 2015-03-20 2018-01-24 Ablynx N.V. Glycosylated immunoglobulin single variable domains
DK3277719T3 (da) 2015-03-31 2022-05-02 Sorriso Pharmaceuticals Inc Polypeptider
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
HK1250011A1 (zh) 2015-03-31 2018-11-23 Sorriso Pharmaceuticals, Inc. 具有蛋白酶可切割接头的肽构建体
NZ777930A (en) 2015-07-16 2025-05-02 Inhibrx Biosciences Inc Multivalent and multispecific dr5-binding fusion proteins
ES2941968T3 (es) 2015-10-01 2023-05-29 The Whitehead Institute For Biomedical Res Marcaje de anticuerpos
RU2018119732A (ru) 2015-10-30 2019-12-03 Аблинкс Нв Полипептиды против il-23
ES2904553T3 (es) * 2015-10-30 2022-04-05 Hoffmann La Roche Fragmentos de anticuerpo modificados con bisagra y procedimientos de preparación
NO2768984T3 (https=) * 2015-11-12 2018-06-09
WO2017081265A1 (en) * 2015-11-12 2017-05-18 Ablynx Nv Improved p2x7 receptor binders and polypeptides comprising the same
CN115925919A (zh) 2015-11-13 2023-04-07 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白可变结构域
MA43260A (fr) * 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
CN120535622A (zh) 2015-11-18 2025-08-26 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
US10544222B2 (en) * 2015-11-18 2020-01-28 Merck Sharp & Dohme Corp. PD1/CTLA4 binders
CR20180279A (es) 2015-11-18 2018-08-24 Merck Sharp & Dohme Enlazadores de ctla4
WO2017089618A1 (en) 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
KR102802241B1 (ko) 2015-12-04 2025-05-07 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드
GB201522539D0 (en) 2015-12-21 2016-02-03 Hexcel Composites Ltd Improvements in or relating to electrically conducting materials
MX2018016413A (es) * 2016-06-23 2019-05-09 Ablynx Nv Ensayos farmacocineticos mejorados para dominios variables unicos de inmunoglobulina.
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
RU2022101604A (ru) 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
SG10202108972RA (en) 2017-01-17 2021-09-29 Ablynx Nv Improved serum albumin binders
HRP20241501T1 (hr) 2017-01-17 2025-01-03 Ablynx Nv Poboljšana veziva albumina u serumu
EP3602056A1 (en) 2017-03-31 2020-02-05 Ablynx N.V. Improved immunogenicity assays
PL3630816T3 (pl) 2017-05-31 2024-08-05 Boehringer Ingelheim International Gmbh Polipeptydy antagonizujące sygnalizację wnt w komórkach nowotworowych
IL302613B2 (en) 2017-09-08 2025-04-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
WO2019063726A1 (en) 2017-09-27 2019-04-04 Elasmogen Ltd SPECIFIC BINDING MOLECULES
WO2019154867A1 (en) * 2018-02-06 2019-08-15 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
AU2019302642B2 (en) 2018-07-10 2025-10-30 Regeneron Pharmaceuticals, Inc. Modifying binding molecules to minimize pre-existing interactions
CN109096394B (zh) * 2018-09-21 2021-11-05 成都阿帕克生物科技有限公司 一种抗葡萄球菌蛋白a的b亚单位的纳米抗体及核酸分子和应用
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
GB201818460D0 (en) * 2018-11-13 2018-12-26 Crescendo Biologics Ltd Single domain antibodies that bind human serum albumin
WO2020181140A1 (en) 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물
WO2020254827A1 (en) 2019-06-21 2020-12-24 Vhsquared Limited Polypeptides
JP7680377B2 (ja) 2019-06-21 2025-05-20 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
GB201914468D0 (en) 2019-10-07 2019-11-20 Crescendo Biologics Ltd Binding Molecules
AU2020403273A1 (en) * 2019-12-11 2022-06-30 Cullinan Oncology, Inc. Anti-CD19 antibodies and multi-specific binding proteins
IL293780A (en) * 2019-12-11 2022-08-01 Cullinan Man Inc Anti-serum albumin antibodies
AR121706A1 (es) * 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
PE20230856A1 (es) 2020-08-17 2023-05-29 Takeda Pharmaceuticals Co Proteinas de union restringidas activadas de forma condicional
CN117903303A (zh) * 2020-08-20 2024-04-19 南京融捷康生物科技有限公司 Il-5的结合分子及其应用
EP4204094A1 (en) * 2020-08-27 2023-07-05 Enosi Therapeutics Corporation Methods and compositions to treat autoimmune diseases and cancer
CN116745316A (zh) 2020-09-04 2023-09-12 武田药品工业有限公司 具有人血清白蛋白结构域的受限条件激活结合蛋白构建体
TW202229335A (zh) * 2020-10-12 2022-08-01 美商健生生物科技公司 用於多方向性生物輸送之生物合成材料及方法
CN113307870B (zh) * 2020-10-30 2022-12-23 上海洛启生物医药技术有限公司 抗il5纳米抗体及其应用
WO2022130013A1 (en) 2020-12-14 2022-06-23 Takeda Pharmaceutical Company Limited Conditionally bispecific binding proteins
CN112341543B (zh) * 2021-01-11 2021-04-23 广东赛尔生物科技有限公司 包含间充质干细胞外泌体的药物组合物在治疗疾病中的应用
TW202304998A (zh) 2021-04-06 2023-02-01 日商武田藥品工業股份有限公司 使用限制性條件活化之結合蛋白的治療方法
TW202330596A (zh) * 2021-11-29 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 經修飾的蛋白或多肽
WO2023110190A1 (en) 2021-12-13 2023-06-22 Heraeus Medical Gmbh Tests and methods for detecting bacterial infection
US20250368756A1 (en) * 2022-01-27 2025-12-04 Janssen Biotech, Inc. Enhanced protein compositions
WO2023164551A1 (en) 2022-02-23 2023-08-31 Takeda Pharmaceutical Company Limited Conditionally bispecific binding proteins
MA71603A (fr) 2022-07-27 2025-05-30 Ablynx Nv Polypeptides se liant à un épitope spécifique du récepteur fc néonatal
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate
CN115819599B (zh) * 2022-11-29 2024-01-16 江苏耀海生物制药有限公司 一种利用重组大肠杆菌分泌表达纳米抗体Cablivi的方法
CN120529914A (zh) 2023-01-09 2025-08-22 奥德赛治疗股份有限公司 抗tnfr2抗原结合蛋白及其用途
JP2026506075A (ja) 2023-02-17 2026-02-20 アブリンクス エン．ヴェー． 新生児型ｆｃ受容体に結合するポリペプチド
WO2024192065A1 (en) 2023-03-14 2024-09-19 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
EP4698909A1 (en) * 2023-04-20 2026-02-25 Xentria, Inc. Methods for detecting an anti-drug antibody (ada) against an anti-tnf alpha antibody
CN121511255A (zh) * 2023-05-17 2026-02-10 奥德赛治疗股份有限公司 经修饰的单结构域抗体
IL325291A (en) 2023-06-29 2026-02-01 Odyssey Therapeutics Inc Anti-TRAILR2 antigen-binding proteins and their uses
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
WO2025049948A1 (en) 2023-08-30 2025-03-06 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
US20250092109A1 (en) 2023-08-30 2025-03-20 Xilio Development, Inc. Vhh masked cytokines and methods of use thereof
US20250129145A1 (en) 2023-09-22 2025-04-24 Ablynx N.V. Bi- and multivalent albumin binders
WO2025080751A2 (en) 2023-10-13 2025-04-17 Odyssey Therapeutics, Inc. Anti-cdh17 antigen-binding proteins and uses thereof
WO2025145329A1 (zh) * 2024-01-03 2025-07-10 苏州智核生物医药科技有限公司 经修饰的免疫球蛋白单一可变结构域
TW202545979A (zh) 2024-01-10 2025-12-01 美商艾希利歐發展股份有限公司 經遮蔽之ｉｌ－２細胞介素及其使用方法
WO2025167664A1 (zh) * 2024-02-07 2025-08-14 原启生物科技(上海)有限责任公司 Ror1抗原结合蛋白及其用途
CN120025456B (zh) * 2024-03-13 2025-11-07 寻济生物科技（北京）有限公司 一种抗vegfa融合构建体及其制备方法和应用
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof
WO2026006708A2 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2026006809A1 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Multispecific molecules binding tnfr2 and cd25 and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
IL127127A0 (en) * 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
ES2852423T3 (es) * 2005-05-20 2021-09-13 Ablynx Nv NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
DE102005023617A1 (de) * 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
JP2007008925A (ja) * 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
US7989219B2 (en) * 2005-05-31 2011-08-02 Canon Kabushiki Kaisha Bispecific capturing molecule
CA2622968A1 (en) * 2005-09-23 2007-03-29 Academisch Ziekenhuis Leiden Vhh for the diagnosis, prevention and treatment of diseases associated with protein aggregates
EA200801166A1 (ru) * 2005-12-01 2008-12-30 Домантис Лимитед Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
CA2632866A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
WO2007085814A1 (en) * 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
EP2121018A2 (en) * 2006-12-13 2009-11-25 Schering Corporation Treating cancer with anti-igf1r antibody 19d12=sch 717454
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
CA2688433A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
WO2008149147A2 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
EP2220120A2 (en) * 2007-11-27 2010-08-25 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
AU2008328726B2 (en) 2007-11-30 2014-06-12 Glaxo Group Limited Antigen-binding constructs
CN102131827A (zh) 2007-12-13 2011-07-20 葛兰素集团有限公司 用于肺部传递给药的组合物
EP2252303A2 (en) 2008-03-21 2010-11-24 Ablynx NV Von willebrand factor specific binders and methods of use therefor
US8020937B2 (en) * 2008-07-31 2011-09-20 Lear Corporation Layered technology for energy management of vehicle seating
CA2733742A1 (en) * 2008-08-14 2010-02-18 Cephalon Australia Pty Ltd Variant domain antibodies
EP2362767B1 (en) 2008-10-29 2017-12-06 Ablynx N.V. Formulations of single domain antigen binding molecules
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
NZ595461A (en) * 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
HUE051430T2 (hu) * 2009-07-10 2021-03-01 Ablynx Nv Eljárás variábilis domének elõállítására
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
PT2513147T (pt) * 2009-12-18 2016-10-11 Sanofi Sa Novos anticorpos antagonistas e seus fragmentos fab contra gpvi e utilizações destes
EP2621953B1 (en) * 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
DK2723769T4 (da) 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
EP2944653A1 (en) * 2011-06-23 2015-11-18 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
SG2014010482A (en) * 2011-08-17 2014-04-28 Glaxo Group Ltd Modified proteins and peptides
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins

Also Published As

Publication number Publication date
EP2987806A2 (en) 2016-02-24
ES2813432T3 (es) 2021-03-23
IL230918A0 (en) 2014-03-31
KR102143506B1 (ko) 2020-08-12
JP2014525752A (ja) 2014-10-02
US20250136721A1 (en) 2025-05-01
AU2016277685A1 (en) 2017-01-19
AU2019201505A1 (en) 2019-03-28
JP6979446B2 (ja) 2021-12-15
UA118833C2 (uk) 2019-03-25
KR20190113996A (ko) 2019-10-08
EP2744822B1 (en) 2020-06-24
EA201490262A1 (ru) 2014-09-30
MA35428B1 (fr) 2014-09-01
JP2020054374A (ja) 2020-04-09
CN108178800B (zh) 2022-06-17
WO2013024059A3 (en) 2014-05-30
KR20140054262A (ko) 2014-05-08
PH12014500380A1 (en) 2022-05-02
CN103917557B (zh) 2018-03-20
US20140227259A1 (en) 2014-08-14
CN103917557A (zh) 2014-07-09
BR112014003679B1 (pt) 2022-08-30
EP2987806A3 (en) 2016-07-13
NZ621203A (en) 2016-03-31
US10808040B2 (en) 2020-10-20
JP2018117623A (ja) 2018-08-02
DOP2014000029A (es) 2014-10-31
CA2845029A1 (en) 2013-02-21
SG10201605891TA (en) 2016-09-29
PE20141522A1 (es) 2014-11-17
EP3339322A3 (en) 2018-10-31
US20210017293A1 (en) 2021-01-21
UY34254A (es) 2013-04-05
TW201321405A (zh) 2013-06-01
EP2744822A2 (en) 2014-06-25
CN108178800A (zh) 2018-06-19
AU2012296961A1 (en) 2014-03-13
MY167125A (en) 2018-08-13
AU2012296961B2 (en) 2017-02-16
WO2013024059A2 (en) 2013-02-21
SG2014010482A (en) 2014-04-28
HK1214281A1 (en) 2016-07-22
AR087521A1 (es) 2014-03-26
KR102162413B1 (ko) 2020-10-07
MX2014001883A (es) 2014-05-27
BR112014003679A2 (pt) 2017-03-07
EA027160B1 (ru) 2017-06-30
EP3339322A2 (en) 2018-06-27
AU2016277685B2 (en) 2019-03-28
WO2013024059A9 (en) 2014-04-03
JP6297976B2 (ja) 2018-03-20

Similar Documents

Publication Publication Date Title
CO7020851A2 (es) Proteínas y péptidos modificados
LTPA2019012I1 (lt) Plazmos kalikreiną surišantys baltymai
IL232247B (en) Polypeptide constructs and uses thereof
EP2753635A4 (en) P53-ACTIVATING PEPTIDES
BR112014004902A2 (pt) peptídeos
DK2920197T3 (da) Prolinlåste sammenhæftede peptider og anvendelser deraf
HRP20150241T1 (xx) Antikancerogeni fuzijski protein
EP2922416A4 (en) MANIPULATED SECRETATED PROTEINS AND METHOD
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
CO7020866A2 (es) Péptidos terapéuticos
EP3546481C0 (en) ANTI-INTERLEUKIN 22 ANTIBODIES (IL-22) AND THEIR USES
EP2688579A4 (en) CATIONIC AROMATIC PEPTIDES AND USES THEREOF
ME02224B (me) Antikancerski fuzioni protein
IL232645B (en) Recombinant proteins and their therapeutic uses
BR112013017488A2 (pt) peptídeos imunogênicos multiméricos e monoméricos
DK2721152T3 (da) Dimere bindingsproteiner baseret på modificerede ubiquitiner
IL237135A0 (en) Peptide library and use thereof
DK3173102T3 (da) FGFR-FC-fusionsprotein og anvendelse deraf
FI20116212L (fi) Polypeptidi
CL2014002180A1 (es) Peptidos antomicrobianos
IL245924B (en) Topk peptides and vaccines including the same
BR112013024323A2 (pt) peptídeos neuroprotetores
EP2742153A4 (en) PROTEIN AND PEPTIDE LIBRARIES
IL236690B (en) Ube2t peptides and vaccines containing the same
IL229956B (en) Mphosphi peptides and vaccines including the same